<div id="readability-page-1"><div><ul> <li>Summit Therapeutics Inc. has reported first quarter 2026 results, with net loss widening to US$189.4 million and basic and diluted loss per share from continuing operations at US$0.24, while also advancing multiple Phase III trials of ivonescimab in non-small cell lung cancer and colorectal cancer.</li> <li>The company’s upcoming presentation of overall survival data from the pivotal Phase III HARMONi-6 trial at the ASCO 2026 Plenary Session, together with the FDA’s acceptance of its Biologics License Application for ivonescimab in EGFR-mutated non-small cell lung cancer and a PDUFA goal date set for November 14, 2026, marks a critical point for its lead asset’s clinical and regulatory profile.</li> <li>With HARMONi-6 overall survival data now headed to an ASCO Plenary, we’ll examine how this could reshape Summit’s investment narrative.</li> </ul><p>Outshine the giants: these 18 early-stage AI stocks could fund your retirement.</p><h2>Summit Therapeutics Investment Narrative Recap</h2><p>To own Summit Therapeutics today, you have to believe ivonescimab can clear key regulatory bars and translate its broad Phase III program into a viable commercial product, despite steep current losses. The widening first quarter 2026 net loss to US$189.4 million does not directly change the near term clinical catalyst, which remains the upcoming HARMONi-6 overall survival data and the FDA’s ivonescimab BLA review, but it does sharpen the immediate financing and cash burn risk.</p> <p>The most relevant recent announcement is the FDA’s acceptance of Summit’s Biologics License Application for ivonescimab in EGFR mutated non small cell lung cancer, with a PDUFA goal date of November 14, 2026. This filing, alongside the HARMONi-6 overall survival data heading to an ASCO Plenary, concentrates attention on whether a single asset can justify the company’s heavy investment and underpin future funding options if the current losses persist.</p> <p>Yet behind the excitement around HARMONi-6, investors should be aware that rising losses and a finite cash runway could force hard choices if...</p> <p>Read the full narrative on Summit Therapeutics (it's free!)</p><p>Summit Therapeutics' narrative projects $848.4 million revenue and $125.2 million earnings by 2029. This implies an earnings increase of about $1.2 billion from -$1.1 billion today.</p><p>Uncover how Summit Therapeutics' forecasts yield a $29.18 fair value, a 81% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/48ed95c3-f060-49d2-9a10-bf7cb1fda776/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/48ed95c3-f060-49d2-9a10-bf7cb1fda776/chart/quote-price"/><figcaption>SMMT 1-Year Stock Price Chart</figcaption></figure> <p>Before this earnings hit, the most optimistic analysts were modeling about US$3.1 billion of revenue and US$1.7 billion of earnings by 2029, which is a far brighter scenario than the consensus view. Given how dependent that bullish case is on one drug across many trials, this latest loss and the coming HARMONi 6 survival readout could push those expectations in very different directions, so it is worth weighing how comfortable you are with such a wide spread in possible outcomes.</p><p>Explore 7 other fair value estimates on Summit Therapeutics - why the stock might be worth over 5x more than the current price!</p><h2>Reach Your Own Conclusion</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Summit Therapeutics research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.</li><li>Our free Summit Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Summit Therapeutics' overall financial health at a glance.</li></ul><h2>Looking For Alternative Opportunities?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</li><li>Uncover the next big thing with 24 elite penny stocks that balance risk and reward.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

SMMT

IBBQ

SBIO

LABU

<p>Summit Therapeutics Inc. reported a widening net loss of $189.4 million for Q1 2026, with a loss per share of $0.24. The company is advancing Phase III trials for ivonescimab and has received FDA acceptance for its Biologics License Application, with a PDUFA goal date of November 14, 2026. The upcoming overall survival data from the HARMONi-6 trial is critical for the company's future, as rising losses and cash burn pose risks. Analysts project significant revenue growth by 2029, but the reliance on a single drug raises concerns about investment viability.</p>

Simplywall

Summit Therapeutics

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider Losses - Has The Bull Case Changed?